Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin.
Netilmicin or tobramycin was administered to 197 patients in a prospective randomized double-blind trial. Of these patients, 140 recipients of nine or more doses of netilmicin or tobramycin could be evaluated for nephrotoxicity. Fifty-five patients were able to cooperate in the administration of serial audiograms. Nephrotoxicity of similar severity developed in 7 of 73 (9.6%) recipients of tobramycin and in 7 of 67 (10.4%) recipients of netilmicin (P greater than 0.05). Mild or slight auditory toxicity developed in 5 of 28 (17.8%) recipients of tobramycin and in 2 of 27 (7.4%) recipients of netilmicin (P greater than 0.05).
D000328:Adult; D000368:Aged; D001309:Auditory Threshold; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D005839:Gentamicins / Q000009:adverse effects*; D006311:Hearing Disorders / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D009428:Netilmicin / Q000009:adverse effects*; D011446:Prospective Studies; D011897:Random Allocation; D014031:Tobramycin / Q000009:adverse effects*
D005839:Gentamicins; D009428:Netilmicin; D003404:Creatinine; D014031:Tobramycin